Biogen (BIIB) announced today the appointment of Matt Griffiths as senior vice president and chief information officer (CIO). He will report to the company’s executive vice president of Technology and Business Solutions, Adriana Karaboutis. Mr. Griffiths was promoted to the CIO role from his position as vice president of Pharmaceutical Operations and Corporate Information Technology, having joined Biogen from Dell earlier this year.
Mr. Griffiths will develop Biogen’s overall strategy for enterprise information technology (IT), including business engagement, global solution development and support, and infrastructure, while also supporting the company’s core business and growing pipeline. Further, he will work closely with groups across Biogen’s technology and business solutions units on efforts to accelerate drug discovery and development through insights from real-world data analytics and improve patient care through the use of mobile, wearable and imaging technologies.
“Matt’s technical expertise, background in analytics and business solutions, and his ability to bridge disparate organizations and disciplines will be critical as technology plays an increasingly important role at Biogen,” said Ms. Karaboutis. “As we continue to advance the development of new therapeutic candidates and gain insights from existing treatments, our ability to harness data becomes increasingly important. I am excited to work with Matt to advance the remarkable opportunities before us.”
Prior to joining Biogen, Mr. Griffiths spent 16 years at Dell where he held numerous IT roles in both Europe and the United States. He was instrumental in driving new technologies and business capabilities through Dell’s manufacturing and supply chain organizations, as well as innovation in IT infrastructure.
Mr. Griffiths serves on the Pharmaceutical Information Systems Association (PISA), a non-profit organization that shares information and IT best practices across larger biotechnology and pharmaceutical companies to further the capabilities of the industry. He has a Bachelor’s Degree in Manufacturing Systems and Manufacturing Management from University of Wales, Cardiff.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.